News

CHMP recommends approval of Rinvoq for psoriatic arthritis and ankylosing spondylitis.- AbbVie

Read time: 1 mins

Published:12th Dec 2020

AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Rinvoq (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis. The CHMP positive opinions are based on results from three pivotal clinical studies in which Rinvoq demonstrated efficacy across multiple measures of disease activity.

Condition: Psoriatic Arthritis

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Cidara Therapeutics reacquires global development and commercial rights to CD 388

Cidara Therapeutics, Inc. a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced that it has entered into a definitive agreement with Johnson & Johnsonto reacquire the exclusive global development and commercial rights to CD 388, which is in development for the prevention of all strains of influenza A and B

1 mins

Drug news

Cidara Therapeutics announces the divestiture of rezafungin rights to MundiPharma

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin

1 min

Drug news

FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older

1 min

See all news